How new melanoma drug accelerates secondary skin cancers
Friday, January 20, 2012 - 09:30
in Health & Medicine
Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin...